Replies to post #141186 on Biotech Values

[DewDiligence]

Not sure I agree with your logic that the absence of a current supply problem is a reason to break orphan exclusivity. If COMP were worried about Gaucher supply problems in the future, that might be a reason to want a third entrant in the marketplace, but that’s a rather different argument than the one you’re making.